@article{246d4520faac441a8229f75f70eafdb0,
title = "Chemo-radiotherapy in non-small cell lung cancer: The role of gemcitabine",
abstract = "Gemcitabine (2′-2′-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects. {\textcopyright} 2006 Oxford University Press.",
keywords = "n/a, n/a",
author = "L. Trodella and D'Angelillo, {R. M.} and S. Ramella and F. Cellini and Francesco Cellini and M. Ciresa and Alfredo Cesario and Pierluigi Granone",
year = "2006",
doi = "10.1093/annonc/mdj950",
language = "English",
volume = "17",
pages = "v52--v54",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Attuale:OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD, ENGLAND, OX2 6DP Kluwer Academic Publishers:Journals Department, PO Box 322, 3300 AH Dordrecht Netherlands:011 31 78 6576050, EMAIL:
[email protected],
[email protected], INTERNET: http://www.kluwerlaw.com, Fax: 011 31 78 6576254",
}